Westpac Banking Corp’s Alnylam Pharmaceuticals ALNY Stock Holding History

Westpac Banking Corp’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$811K	Sell	2,452 -2,859	-54%	-$973K	0.06%	220
2025 Q4	$2.11M	Buy	5,311 +3,956	+292%	+$1.75M	0.13%	149
2025 Q3	$618K	Hold	1,355	–	–	0.04%	250
2025 Q2	$442K	Sell	1,355 -3,718	-73%	-$1.03M	0.03%	265
2025 Q1	$1.37M	Sell	5,073 -5,487	-52%	-$1.41M	0.1%	187
2024 Q4	$2.48M	Buy	10,560 +4,819	+84%	+$1.27M	0.16%	141
2024 Q3	$1.58M	Buy	5,741 +4,274	+291%	+$1.11M	0.11%	186
2024 Q2	$356K	Hold	1,467	–	–	0.03%	276
2024 Q1	$219K	Sell	1,467 -45	-3%	-$7.51K	0.02%	335
2023 Q4	$289K	Buy	1,512 +566	+60%	+$96.4K	0.02%	304
2023 Q3	$168K	Hold	946	–	–	0.01%	402
2023 Q2	$180K	Sell	946 -10,316	-92%	-$2.05M	0.01%	370
2023 Q1	$2.26M	Hold	11,262	–	–	0.03%	505
2022 Q4	$2.68M	Buy	11,262 +861	+8%	+$184K	0.04%	449
2022 Q3	$2.08M	Buy	10,401 +1,877	+22%	+$358K	0.03%	500
2022 Q2	$1.24M	Hold	8,524	–	–	0.02%	626
2022 Q1	$1.39M	Hold	8,524	–	–	0.02%	643
2021 Q4	$1.45M	Sell	8,524 -2,445	-22%	-$454K	0.02%	637
2021 Q3	$2.07M	Hold	10,969	–	–	0.02%	580
2021 Q2	$1.86M	Hold	10,969	–	–	0.02%	622
2021 Q1	$1.55M	Hold	10,969	–	–	0.02%	606
2020 Q4	$1.43M	Hold	10,969	–	–	0.02%	640
2020 Q3	$1.6M	Hold	10,969	–	–	0.02%	581
2020 Q2	$1.62M	Hold	10,969	–	–	0.02%	549
2020 Q1	$1.19M	Hold	10,969	–	–	0.02%	553
2019 Q4	$1.26M	Buy	10,969 +5,280	+93%	+$526K	0.02%	639
2019 Q3	$458K	Hold	5,689	–	–	0.01%	801
2019 Q2	$413K	Hold	5,689	–	–	0.01%	679
2019 Q1	$532K	Hold	5,689	–	–	0.01%	640
2018 Q4	$415K	Hold	5,689	–	–	0.01%	738
2018 Q3	$498K	Hold	5,689	–	–	0.01%	654
2018 Q2	$560K	Hold	5,689	–	–	0.01%	613
2018 Q1	$678K	Hold	5,689	–	–	0.01%	570
2017 Q4	$723K	Buy	+5,689	New	+$715K	0.02%	536
2016 Q4	–	Sell	-4,274	Closed	-$290K	–	820
2016 Q3	$290K	Hold	4,274	–	–	﹤0.01%	762
2016 Q2	$237K	Buy	4,274 +1,057	+33%	+$66.6K	﹤0.01%	824
2016 Q1	$202K	Hold	3,217	–	–	﹤0.01%	802
2015 Q4	$303K	Sell	3,217 -12,164	-79%	-$1.13M	﹤0.01%	771
2015 Q3	$1.24M	Buy	15,381 +14,882	+2,982%	+$1.65M	0.01%	502
2015 Q2	$59.8K	Buy	+499	New	+$59.6K	﹤0.01%	781

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Westpac Banking Corp's ALNY Position: Q1 2026 in Review

Westpac Banking Corp reduced its Alnylam Pharmaceuticals (ALNY) stake by 54% in Q1 2026, selling an estimated $973K and leaving 2,452 shares worth $811K. The position accounts for 0.06% of the portfolio, ranked #220.

Westpac Banking Corp first reported a position in ALNY in Q2 2015 and has held it in 40 quarters since. The position peaked at $2.68M in Q4 2022. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Westpac Banking Corp held 2,452 shares of Alnylam Pharmaceuticals worth $811K as of Q1 2026.
Westpac Banking Corp sold 2,859 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $973K.
Alnylam Pharmaceuticals made up 0.06% of Westpac Banking Corp's portfolio in Q1 2026, its #220 holding.
Westpac Banking Corp first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 40 quarters since.
Westpac Banking Corp's Alnylam Pharmaceuticals position peaked at $2.68M in Q4 2022.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Westpac Banking Corp's 13F filing for Q1 2026, filed 12 May 2026.